THERAVANCE
A Phase 2, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of an inhaled Pan-Janus Kinase Inhibitor, TD-0903, to treat symptomatic acute lung injury associated with COVID-19.
Type: Interventional
Site and lead:
- Wythenshawe Hospital: Dr Rob Lord
Patient group: COVID-19 patients requiring supplemental oxygen
Intervention:
- Pan-Janus Kinase Inhibitor (TD-0903)